该行表示，根据石药最新公告，与阿斯利康合作的关键临床候选药物为SYH2082，长效GLP-1R/GIPR双 激动剂，现已进入I期临床。该行对此长效GLP-1平台了解甚少。SYH2082刚在中国启动I期研究。需等 待管理阶层揭露其设计细节及潜在临床开发路径，方能进行价值量化评估。该行维持"中国创新药进入 全球管线"的长期正面判断，但建议投资者仔细审视BD公告前已被市场计入预期的资产估值因素，并对 双方合作进展进行深度量化评估。 该行认为siRNA进入肥胖维持市场，将对所有胜肽类方案构成真正威胁。siRNA药物切入减重及肌保市 场，或最终挤压肽基肥胖疗法。该行密切追踪Arrowhead和Wave siRNA资产进展后，认为肥胖维持领域 正日益拥挤。建议投资人关注未来siINHBE和siALK7靶点对减重维持市场的影响。 招商证券国际发布研报称，石药集团(01093)与阿斯利康(AZN.US)达成历史性交易公告，表示看好交 易，但需等待石药或阿斯利康披露更多长效GLP-1全球开发细节。重申"中性"评级，认为短期基本面仍 存隐忧。 ...

2 February 2026 | 8:22AM HKT Equity Research CSPC Pharma (1093.HK): A landmark deal with AZ on long-acting GLP-1 and platform technologies; Buy A new breakthrough in license-out: CSPC signed a deal with AstraZeneca (AZN, covered by Rajan Sharma) for the development of long-acting peptide medicine, utilising sustained-release delivery technology platform and AI-driven peptide drug discovery platform. Besides platform-based cooperation, CSPC will license-out the ex-China rights of eight assets, including 1) o ...

在中国的最后一天，斯塔默在上海 C ity W alk ，逛了逛豫园的花灯展，在上海街头买了一盒蝴蝶酥，还颇有兴致地观赏上海大学生设计的花灯。 他非常喜欢其中一只马头灯饰，纹样是英国标志性的苏格兰红绿格纹。他曾向陪同的中国官员询问 "马年"的寓意，对方解释："马在中国文化中象 征着幸运与成功，寓意'马到成功、一马当先'。" 点击按钮▲立即收听 " 欧洲国家们从二战后持续 80 多年的、繁荣而优雅的梦境里醒了过来，开始审视自身的困境，并重新规划路线。 " 文 /巴九灵（微信公众号：吴晓波频道） 英国首相斯塔默结束了为期 4 天的访华行程。 这是英国首相时隔 8 年再次访华。路透社报道称，英国与中国将寻求重启 21 世纪初的两国关系，那时被称为中英关系的"黄金时代"。 英国商贸大臣凯尔则对中国媒体表示： "我认为我们已超越'黄金时代'的模式。我们曾陷于走走停停的误区，而如今中国与英国进入了以长远战略 视角推进双边关系的新阶段。" 中欧 "破冰"不止于此。这是多年未见的一幕：不到三个月的时间里，欧洲各国轮番出动，带着浩浩荡荡的代表团来到中国。 去年 11 月，西班牙国王费利佩六世携王后来华，这是西班牙国王时隔 18 ...

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - On January 30, 2023, the report highlights that the company has signed a strategic R&D cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform [3] - AstraZeneca will gain global exclusive rights to the company's weight management product portfolio, which includes a clinical-ready project SYH2082 and three preclinical projects targeting obesity and weight-related issues [3] - The company is set to receive $1.2 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [3] Summary by Sections Industry Overview - The report emphasizes the increasing recognition of Chinese innovative pharmaceutical companies by international multinational corporations (MNCs), particularly through the recent collaboration with AstraZeneca [4] - The report also notes AstraZeneca's plan to invest $15 billion in China by 2030 to expand drug manufacturing and R&D, leveraging China's scientific capabilities and manufacturing strengths [4] Investment Strategy - The report suggests that the global competitiveness of Chinese innovative pharmaceutical companies is continuously improving, with a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [5] - It recommends paying attention to emerging fields like small nucleic acid drugs, radioactive drugs, and CAR-T therapies, highlighting specific companies to watch [5] Market Performance - The pharmaceutical sector experienced a decline of 3.31% last week, ranking 20th among 28 industries, while the Hong Kong pharmaceutical sector fell by 2.98% [9][30] - The report indicates that the valuation of the pharmaceutical sector is at 32.45 times (TTM), with a premium of 15.83% compared to the overall A-shares [23]

【#斯塔默访华后唐宁街发声#】#斯塔默点赞泡泡玛特#据参考消息援引英国《独立报》网站1月31日报 道，基尔·斯塔默结束了此次中国之行，对两国达成的经贸合作文件以及与泡泡玛特等企业在英投资表 示赞许，泡泡玛特是爆款玩偶拉布布的出品方。这位英国首相在对中国进行了为期四天的访问后于1月 31日离开上海。他在访问期间多次表示，自己做出的重启英中交往的决定将为英国民众带来切实利益。 斯塔默表示："我们为英中交往确立了稳定、清晰和长远的战略，以此为英国企业和工薪阶层争取实实 在在的好处。"此次访华以经贸合作为核心，斯塔默率领50余家英国大企业高管和机构代表随访。唐宁 街方面表示，此次访问促成了出口贸易和市场准入方面的协议，同时中国企业也将在英国进行数亿英镑 的投资。其中，拉布布的出品方泡泡玛特承诺将在英国开设7家门店，包括一家位于伦敦牛津街的旗舰 店。此外，香港《南华早报》网站1月31日刊登社论，文章以《斯塔默访华凸显对华非对抗的好处》为 题，指出斯塔默希望摆脱保守党执政时期英中关系的"冰河时代"。文章认为，斯塔默对中国的访问是朝 这个方向迈出的一大步。在美国总统特朗普的贸易战和夺取格陵兰岛言论的背景下，英国和欧盟国家与 ...

Core Viewpoint - The article discusses the renewed commitment of the UK government to strengthen bilateral relations with China, moving beyond previous tensions and aiming for a stable and comprehensive partnership that fosters mutual economic opportunities [3][5]. Group 1: Bilateral Relations - The UK government, under Prime Minister Starmer, aims to establish a long-term and stable relationship with China, moving past the "ice age" described by Starmer regarding previous administrations' handling of China [5][6]. - The recent visit by UK Trade and Business Secretary Peter Kyle to China, his second visit in four months, underscores the government's commitment to enhancing bilateral trade and investment [3][5]. - The UK government has introduced a ten-year modern industrial strategy aimed at supporting key industries like advanced manufacturing and clean energy, which aligns with China's "14th Five-Year Plan" [6][8]. Group 2: Economic Opportunities - The UK seeks to attract Chinese investments in high-end manufacturing, highlighting the complementary strengths of both nations in various sectors [8][9]. - AstraZeneca plans to invest over 100 billion RMB in China by 2030, focusing on drug research, manufacturing, and innovation, indicating strong bilateral investment flows [8][9]. - The UK and China have agreed to conduct a feasibility study for a service trade agreement, aiming to leverage their respective strengths in sectors like creative industries, professional services, and healthcare [9][10]. Group 3: Industry Cooperation - The article emphasizes the potential for collaboration in rapidly growing sectors such as life sciences, green technology, and artificial intelligence, where both countries have significant advantages [10]. - The presence of diverse industries in the UK delegation, including cultural and creative sectors, showcases the UK's economic vitality and the broad prospects for cooperation with China [9][10].

Core Insights - AstraZeneca is set to list on the New York Stock Exchange, aiming to strengthen its investment presence in the U.S., its largest market [1][10] - The company is making significant investments in China, including a $15 billion commitment through 2030, to enhance manufacturing and R&D capabilities [4][10] - AstraZeneca's strategy reflects a broader trend in the pharma industry, where companies are increasingly looking to China for innovation as patents on blockbuster drugs expire [2][3] Investment and Partnerships - AstraZeneca's investment in China will cover the entire value chain from drug discovery to manufacturing, highlighting its commitment to Chinese innovation [5] - The company has partnered with Hong Kong-listed CSPC Pharmaceuticals to bolster its obesity portfolio, involving an upfront payment of $1.2 billion and potential additional payments of $17.3 billion based on milestones [6][7] - This partnership is part of a growing trend of licensing deals between Big Pharma and Chinese biotechs, with 57 such deals reported in 2025 [14] Market Dynamics - The U.S. market presents pricing challenges that are pressuring Big Pharma, making the Chinese market increasingly important for revenue and research [2][3][10] - AstraZeneca's commitment to China is underscored by its recent actions, despite facing regulatory scrutiny in the past [12][13] - The Chinese biopharma sector is evolving rapidly, with a focus on next-generation therapeutics and efficient clinical trial processes, positioning it as a potential leader in biotechnology [15][16]

医药周报 20260130 从 JPM 大会挖掘 FIC 靶点三期数据验证节点 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从 JP Morgan 大会看 2026 MNC 密集验证新靶点 推荐 维持评级 [Table_Author] | 分析师 张金洋 | | --- | | 执业证书： S0590525120012 | | 邮箱： zhangjinyang@glms.com.cn | | 分析师 胡偌碧 | | 执业证书： S0590525120011 | | 邮箱： huruobi@glms.com.cn | | 分析师 王彦迪 | | 执业证书： S0590525120015 | | 邮箱： wangyandi@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 医药 沪深300 相关研究 本公司具备证券投资咨询业务资格，请务必阅读最后一页免责声明 证券研究报告 1 风险提示：1）医保、集采政策导致价格不及预期；2）临床进度或上市时间不及预期；3）行业竞争 格局的不确定性；4）地缘政治风险；5）下游投融资及需求复苏不及 ...

Core Insights - AstraZeneca PLC is positioned as a leading healthcare stock for 2026, with a significant $15 billion investment in China aimed at expanding manufacturing and R&D capabilities by 2030 [1][2] Investment and Expansion - The investment will enhance AstraZeneca's capabilities in cell therapy and radioconjugates, while also fostering deeper healthcare collaborations between China and the UK [1][2] - The company plans to grow its workforce in China to over 20,000 and expand facilities in Wuxi, Taizhou, Qingdao, and Beijing, with additional sites planned [2] Financial Performance Expectations - Guggenheim has reiterated a Buy rating for AstraZeneca, anticipating strong fourth-quarter and 2025 financial results, with expectations of high single-digit revenue growth around $58.5 billion and double-digit EPS growth reaching $9.15 per share [3] - AstraZeneca is expected to guide for mid-single-digit revenue growth, surpassing consensus estimates, and project low double-digit earnings growth against forecasts of 10-12% [4] Pipeline and Future Outlook - Confidence in AstraZeneca's 2030 outlook is increasing as the company advances its pipeline to mitigate the impact of upcoming patent expirations for key products like Imfinzi and Tagrisso [4] - Investors are closely monitoring updates on several candidates, including oral GLP-1 candidate AZD5004 and amylin AZD6234, to strengthen its cardiovascular and metabolic portfolio [4]

Core Viewpoint - AstraZeneca announced a plan to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, marking its largest strategic investment in the country since entering the market in 1993. This investment aims to enhance its drug production and R&D capabilities, reflecting a shift in China's role from an "important market" to a "global innovation hub" [1][2]. Group 1: Investment and Strategic Goals - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, significantly enhancing AstraZeneca's capabilities in cell therapy and antibody-drug conjugates [5][6]. - AstraZeneca's investment is expected to deepen its R&D presence in China, with major strategic R&D centers in Beijing and Shanghai collaborating with over 500 clinical hospitals [5][6]. - The company aims to leverage partnerships with leading biotech firms in China to promote local innovations globally, with a focus on breakthrough therapies [6][9]. Group 2: Market Dynamics and Trends - China's pharmaceutical market is undergoing structural changes, with a record number of innovative drugs approved for market entry, indicating a trend towards diversified innovative therapies [2][9]. - Approximately one-third of global licensing transactions are related to Chinese biopharmaceutical companies, with clinical trials in cutting-edge fields like cell therapy and ADCs accounting for over 30% of global totals [2][9]. - The collaboration between AstraZeneca and Chinese firms, such as the recent deal with CSPC Pharmaceutical Group worth up to 18.5 billion USD (approximately 128.5 billion RMB), exemplifies the growing trend of win-win partnerships in the industry [2][6]. Group 3: Policy and Regulatory Environment - Recent reforms in China's drug approval system have allowed for synchronized global R&D pipelines, significantly reducing the time for new drugs to enter the Chinese market [9][15]. - The Chinese government is actively promoting foreign investment in the healthcare sector, creating a more stable and predictable environment for multinational pharmaceutical companies [15][16]. - AstraZeneca's investment aligns with China's "Healthy China 2030" initiative, focusing on improving disease prevention and access to innovative drugs for underserved populations [15][16]. Group 4: Innovation and Talent Development - AstraZeneca's investment strategy includes a strong emphasis on talent development, with plans to expand its workforce in China to over 20,000 employees and establish programs to cultivate future scientific leaders [12][13]. - The company has already invested in over 31 Chinese innovative enterprises, facilitating numerous global licensing agreements, which highlights the "foreign enterprise + local innovation" model as a new paradigm for foreign pharmaceutical companies in China [12][13]. - The implementation of advanced manufacturing technologies at AstraZeneca's facilities, such as the Wuxi base, has led to significant improvements in production efficiency and energy consumption [12][13].